Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II-III randomized study of bevacizumab plus chemotherapy vs chemotherapy alone in extensive-stage small cell lung cancer
2009-010187-42Phase 2Completed
- Sponsor
- IFCT
- Start
- Mar 2009
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised trial of bevacizumab in small cell lung cancer (SCLC) (2 arms), sponsored by IFCT. Primary endpoints: Objective response rate after 4 cycles (Phase II primary endpoint) and Progression-free survival. Started Mar 2009; status: completed.
02
Drugs
bevacizumab
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on 2009-010187-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-010187-42.